Analyst Ratings For Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Today, HC Wainwright reiterated its Buy rating on Adamas Pharmaceuticals Inc (NASDAQ:ADMS).
There are 8 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Adamas Pharmaceuticals Inc (NASDAQ:ADMS) is Buy with a consensus target price of $42.8750 per share, a potential 260.60% upside.
Some recent analyst ratings include
- 11/5/2018-Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had its Buy rating reiterated by HC Wainwright
- 11/5/2018-Adamas Pharmaceuticals Inc (NASDAQ:ADMS) gets downgraded to Neutral by Mizuho
- 10/19/2018-Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had its Outperform rating reiterated by Leerink Swann
- 10/5/2018-Adamas Pharmaceuticals Inc (NASDAQ:ADMS) gets downgraded to Neutral by Bank of America with a price target of $25.00
- On 9/21/2018 Alfred G Merriweather, CFO, sold 1,665 with an average share price of $19.18 per share and the total transaction amounting to $31,934.70.
- On 6/21/2018 Jennifer J. Rhodes, Insider, sold 1,002 with an average share price of $25.48 per share and the total transaction amounting to $25,530.96.
- On 6/21/2018 Richard King, COO, sold 2,501 with an average share price of $25.48 per share and the total transaction amounting to $63,725.48.
- On 3/21/2018 Christopher B Prentiss, CAO, sold 567 with an average share price of $25.98 per share and the total transaction amounting to $14,730.66.
- On 3/21/2018 Gregory T Went, CEO, sold 4,541 with an average share price of $25.75 per share and the total transaction amounting to $116,930.75.
- On 3/21/2018 Rajiv Patni, Insider, sold 1,252 with an average share price of $25.94 per share and the total transaction amounting to $32,476.88.
- On 12/21/2017 Jennifer J. Rhodes, Insider, sold 440 with an average share price of $32.30 per share and the total transaction amounting to $14,212.00.
About Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Recent Trading Activity for Adamas Pharmaceuticals Inc (NASDAQ:ADMS)
Shares of Adamas Pharmaceuticals Inc closed the previous trading session at 11,89 −5,08 29,94 % with 11.7 shares trading hands.